113¦~12¤ë¸¹ ¹D ªk ªk °T (392) |
DEEP & FAR |
|
±M§Q»¡©ú®Ñ¹ï¥ý«e§Þ³Nªº§åµû³Q¥Î¨Ó¥H¦³§Q©ó±M§QÅv¤Hªº¤è¦¡¸ÑÄÀ½Ð¨D¶µ (In re Abbott Diabetes Care Inc.,¬ü°êÁp¨¹¨µ°j¤W¶Dªk°|2012¦~9¤ë28¤é°µ¥X¨M©w) |
§d¨Ø¬Â ±M§Q¤G²Õ¥D¥ô ¡D¥xÆW¤j¾Ç¹AÃÀ¨t¾Ç¤h ¡D¥xÆW¤j¾Ç¹AÃÀ©ÒºÓ¤h |
|
Belkin International, Inc. ´£¥X¤F¹ï¬ü°ê±M§QNo.
7,035,381ªº¦h¤è¦A¼f¬dªº½Ð¨D¡AÁnºÙ¡G°ò©ó¥|¥÷²ßª¾§Þ³N¤ÞÃÒ¤åÄm¡AÃö©ó½Ð¨D¶µ1-32¥i±M§Q©Ê¦s¦b³\¦h¹ê½è©ÊijÃD¡C¬ü°ê±M§Q°Ó¼Ð§½§½ªø¡G(1)¦]¬°°ò©ó¨ä¤¤¤@¥÷¤ÞÃÒ¤åÄmªº¹w¨£Ä³ÃD½T¹ê¤Þ°_Ãö©ó½Ð¨D¶µ1-3¤Î8-10ªº¥i±M§Q©ÊijÃD¡A¦]¦¹§åã¤F¹ï½Ð¨D¶µ1-3¤Î8-10ªº½Ð¨D¡F¥H¤Î(2)»é¦^°ò©ó¨ä¾l¤ÞÃÒ¤åÄm¹ï½Ð¨D¶µ4-7¤Î11-32ªº½Ð¨D¡CBerklin´£¥X¥Ó½Ð¡An¨D§½ªø¹ï»é¦^½Ð¨D¶µ4-7¤Î11-32ªº¦A¼f¬d¶i¦æ½Æ¼f¡A¦ý¸Ó¥Ó½Ð³Q»é¦^¡CBelkinÀH«á¦VU.S.
PTO±M§Q¶DÄ@¤Î½Ä¬ð©eû·|¡]²{¬°U.S. PTO±M§Q¼f§P¤Î¶DÄ@©eû·|¡^´£¥X¶DÄ@¡A½èºÃ¼f¬dû¥¼¯à¦P¼Ë»é¦^½Ð¨D¶µ4-7¤Î1-32¡A¦ý¸Ó©eû·|»{¬°¨äµLÅv§P¨M¡G°ò©ó¤ÞÃÒ¤åÄm¡A½Ð¨D¶µ4-7¤Î11-32¬O§_¦s¦b¹ê½èªº·s¥i±M§Q©ÊijÃD¡F¦¹¥~¡AÁÙ¨S¦³´N©Ò¤Þ¥Îªº°Ñ¦Ò¤åÄm°w¹ï¥i±M§Q©Ê°µ¥X³Ì²×§P¨M¡A¦]¦¹µL¥ô¦ó¨Æ°È¥i¶DÄ@¡C §P¨M¡GÁp¨¹¨µ°j¤W¶Dªk°|¦P·N©eû·|ªºÆ[ÂI¡A§Y»é¦^Belkin¹ï½Ð¨D¶µ4-7¤Î11-32¦A¼f¬dªº½Ð¨D¬O¡u¤£¥i¶DÄ@ªº¡v¡C[ªk°|¤]«ü¥X¡A¨ä¨Ã¥¼¾A¥Î¦bAIA¹{¥¬¤§¤é¡]2011¦~9¤ë16¤é¡^¤§«e´£¥Xªº¦h¤è¦A¼f¬d×¥¿®×¡C³o¸Ì»Ýn«ü¥Xªº¬O¡A¸gAIA×qªº35 U.S.C. ¡±314(d)³W©w¡A¡u§½ªø¨Ì¾Ú¦¹±ø´Ú¹ï¬O§_¶i¦æ¦h¤è¼f¬dªº¨M©wÀ³¬O³Ì²×ªº¥B¤£¥i¶DÄ@ªº¡v¡C |
||
~The End~ |
||